Ikena Oncology (NASDAQ:IKNA) Earns “Outperform” Rating from William Blair

Ikena Oncology (NASDAQ:IKNAGet Free Report)‘s stock had its “outperform” rating reiterated by William Blair in a report issued on Thursday, RTT News reports.

Several other equities analysts also recently commented on IKNA. HC Wainwright decreased their price target on shares of Ikena Oncology from $18.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 9th. Wedbush initiated coverage on shares of Ikena Oncology in a report on Thursday, September 21st. They set an “outperform” rating and a $11.00 target price on the stock.

Read Our Latest Analysis on IKNA

Ikena Oncology Price Performance

NASDAQ IKNA traded up $0.09 on Thursday, reaching $1.49. The stock had a trading volume of 277,710 shares, compared to its average volume of 114,553. The company has a market cap of $63.03 million, a P/E ratio of -0.92 and a beta of 0.78. The firm has a fifty day moving average of $3.83 and a two-hundred day moving average of $5.17. Ikena Oncology has a 1-year low of $1.02 and a 1-year high of $7.64.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System acquired a new stake in shares of Ikena Oncology during the 2nd quarter worth approximately $46,000. Wells Fargo & Company MN boosted its holdings in shares of Ikena Oncology by 2,913.6% in the 2nd quarter. Wells Fargo & Company MN now owns 8,227 shares of the company’s stock valued at $54,000 after purchasing an additional 7,954 shares in the last quarter. Millennium Management LLC bought a new position in shares of Ikena Oncology in the 4th quarter valued at $27,000. American International Group Inc. acquired a new position in shares of Ikena Oncology during the 2nd quarter worth $67,000. Finally, SG Americas Securities LLC acquired a new position in shares of Ikena Oncology during the 3rd quarter worth $46,000. Institutional investors and hedge funds own 86.01% of the company’s stock.

About Ikena Oncology

(Get Free Report)

Ikena Oncology, Inc operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway.

Featured Stories

Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.